Invion

Invion Days Inventory Outstanding

The Days Inventory Outstanding (DIO) of Invion (IVX.AX) as of Oct 29, 2026 is -164.17.

Days Inventory Outstanding

-164.17

YoY

-130.36 M%

Last updated:

Days Inventory Outstanding (DIO) of Invion is 2024 -164.17 . Days Inventory Outstanding (DIO) of Invion was 2023 0.00 . It decreases by -130.36 M% lower compared to the previous year.

The Invion Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2014
-105.60 AUD
Jan 1, 2015
-77.60 AUD
Jan 1, 2016
-178.99 AUD
Jan 1, 2017
-9.48 AUD
Jan 1, 2018
-90.31 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2023
0.00 AUD
Jan 1, 2024
-164.17 AUD
The Invion Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
-164.17-130.36 M%
0.00—
0.00-100.00%
-90.31+852.60%
-9.48-94.70%
-178.99+130.65%
-77.60-26.51%
-105.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Days Inventory Outstanding (DIO) of Invion is -164.17 in 2024.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Invion since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Invion

All Key Metrics — Invion